Macrocyclolux (Gadoteric Acid)

Macrocyclolux is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve signal intensity across several anatomical regions.

• Magnetic Resonance Imaging of the brain: Improves visualization of lesions, tumors, and vascular structures.
• Magnetic Resonance Imaging of the spine: Enhances detection of disc pathology, spinal cord lesions, and inflammatory changes.
• Magnetic Resonance Imaging of the abdomen and pelvis: Increases contrast between organs and focal lesions for better characterization.

• Gadoteric Acid acts as a paramagnetic agent that shortens the T1 relaxation time of nearby water protons. When administered intravenously, it distributes into the extracellular space and alters local magnetic fields, leading to increased signal intensity on T1‑weighted MRI sequences. This property enables radiologists to differentiate normal tissue from pathology with greater clarity.

Gadoteric Acid may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild, often resolves without intervention.
• Headache: transient discomfort following injection.
• Injection site pain or warmth sensation: brief local reaction.
• Dizziness: mild and self‑limiting.
• Vomiting: occasional, usually mild.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): requires immediate medical attention.
• Nephrogenic systemic fibrosis (NSF): rare, associated with severe renal impairment.
• Cardiovascular collapse: extremely rare but potentially life‑threatening.

Macrocyclolux should be used with careful consideration of patient‑specific factors.

• Renal function assessment: evaluate glomerular filtration rate before administration.
• History of hypersensitivity: avoid in patients with known gadolinium or contrast agent allergy.
• Pregnancy: use only if clearly needed; safety data are limited.
• Pediatric use: dose and safety should be determined by a qualified physician.
• Severe renal impairment: contraindicated or requires special risk‑benefit assessment.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Gadoteric Acid may interact with other agents that affect renal function or contrast efficacy.

Major Interactions (Avoid)

• Concurrent gadolinium agents: may increase cumulative gadolinium exposure.
• High‑dose NSAIDs or aminoglycosides: can exacerbate renal toxicity, raising NSF risk.
• Chelating agents (e.g., deferoxamine): may reduce gadolinium binding and effectiveness.

Moderate Interactions (Monitor Closely)

• Diuretics: monitor fluid and electrolyte balance.
• Metformin: assess renal function to avoid accumulation.
• Beta‑blockers: observe for potential hypotensive response during injection.